Aripiprazole Versus Haloperidol in Combination With Clozapine for Treatment-Resistant Schizophrenia

Autor: Simone Accordini, Marianna Purgato, Michela Nosè, Corrado Barbui, Andrea Cipriani, Francesca Girlanda, Michele Tansella
Rok vydání: 2013
Předmět:
medicine.medical_specialty
Time Factors
Aripiprazole
Drug Resistance
Kaplan-Meier Estimate
Quinolones
Disease-Free Survival
Piperazines
law.invention
Pharmacotherapy
Randomized controlled trial
law
Internal medicine
mental disorders
medicine
Haloperidol
Humans
Pharmacology (medical)
Psychiatry
Clozapine
Proportional Hazards Models
Psychiatric Status Rating Scales
clozapine
schizophrenia
clozapine
randomized controlled trial
antipsychotics
combination strategies
combination strategies
medicine.disease
schizophrenia
antipsychotics
Psychiatry and Mental health
Treatment Outcome
Italy
Schizophrenia
Multivariate Analysis
randomized controlled trial
Psychiatric status rating scales
Linear Models
Drug Therapy
Combination
Schizophrenic Psychology
Treatment resistant schizophrenia
Psychology
Antipsychotic Agents
medicine.drug
Zdroj: Journal of Clinical Psychopharmacology. 33:533-537
ISSN: 0271-0749
Popis: BACKGROUND: Long-term studies for patients with resistant schizophrenia are necessary to assess the effectiveness of combination strategies on persisting positive symptoms. AIMS AND METHODS: This multicenter, naturalistic, randomized, superiority study (ClinicalTrials.gov identifier: NCT00395915) aimed to compare clinical efficacy and tolerability of haloperidol versus aripiprazole as combination treatment with clozapine in patients with resistant schizophrenia. RESULTS: One hundred six patients were followed up for 12 months. After 12 months, the proportion of patients who discontinued treatment was not significantly different between aripiprazole and haloperidol (37% vs 28%, respectively; P = 0.431). The change in the Brief Psychiatric Rating Scale score was similar in the aripiprazole and haloperidol groups (-7.0 vs -7.9, respectively; P = 0.389), whereas the tolerability total score decreased significantly more in the aripiprazole group (-7.2 vs -2.3; P = 0.008). CONCLUSIONS: While the effectiveness of clozapine augmentation with a second antipsychotic agent is not clearly demonstrated yet, results from this study suggest that augmentation with aripiprazole offers no substantial benefit over haloperidol in efficacy. Aripiprazole was perceived more tolerable than haloperidol, but it is uncertain how this finding may translate into the real world of clinical practice.
Databáze: OpenAIRE
Externí odkaz: